The Catalyst

Archive

11.22.13 | By Kaelan Hollon

With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.

11.19.13

Prostate cancer is the second-most common form of cancer affecting men. In 2013, it is estimated that nearly 240,000 American men will be diagnosed with the disease and 29,000 will die from it.

11.15.13 | By Salvatore Alesci

The newly released American Heart Association (AHA) and American College of Cardiology (ACC) Guidelines on the Treatment of Blood Cholesterol and Lifestyle Management to Reduce Atherosclerotic Cardiovascular Risk in Adults have received a great deal of attention over the last couple days and are certain to stimulate further discussion as p

11.15.13

Guest Post from Erin Mullen, PhRMA Associate VP and Director of Rx Response

11.14.13 | By Dr. Bill Chin

The healthcare community is at an important juncture; we must work together to ensure that policies and regulations align to help us meet the unique challenges and full potential of personalized medicine. Science and technology drive what we can achieve, but they also evolve over time.

11.14.13

In science – and especially medicine -- there are celebrated men and women whose life work has changed the world.  Doctors Salk and Sabine and their polio vaccines come quickly to mind.  Because of their work, people around the world need never fear the scourge of polio.

11.13.13

With nearly 1,700 care locations throughout the country and serving more than eight million Veterans, service members and military families each year, the Veterans Health Administration, part of the U.S. Department of Veterans Affairs (VA), is the largest integrated health care system in the country.

11.13.13
The report, "Research in Your Backyard:  Pharmaceutical Clinical Trials in Massachusetts," shows widespread clinical research underway throughout the state, including Worcester where we released the report yesterday with the
11.12.13 | By John Castellani

Over the last few weeks we have devoted a fair bit of time and energy on Alzheimer’s disease. Why? It is one of the most complex diseases we face, it currently afflicts more than 5 million people in the U.S. and its current trajectory is worrisome to say the least.

11.08.13

The phrase “strength in numbers” often rings true for the biopharmaceutical industry. This week we were reminded that when it comes to furthering innovation, collaboration is essential to creating a path forward and finding ways to improve patients’ lives.

11.07.13 | By Preet Bilinski

Have you heard of  Batten disease? Or  of Pompe disease? Niemann-Pick Disease? These are just a few of the 7,000 rare diseases that over 30 million Americans live with every day. Another rare disease that you may not be familiar with is Mitochondrial disease. Unfortunately, Art Estopian is too familiar with the disease.

11.05.13

Today, Alzheimer’s affects more than five million people in America.

11.05.13 | By John Castellani

Last week, I took part in an interesting multi-stakeholder roundtable convened by NEHI and the California Healthcare Institute (CHI).

11.05.13 | By John Castellani

The U.S. pharmaceutical supply chain is the most secure in the world in part because of strong industry and government collaboration.  One benefit is that American patients can have confidence that the prescription medications they purchase from a reputable pharmacy are true to the label.

11.04.13 | By Raju Kucherlapati, Ph.D.

Personalized Medicine was an emerging field of medicine in 2005 when we first held what was to become an annual event, our personalized medicine conference. The importance of personalized medicine was given a boost by the then U.S. Secretary of Health and Human Services, Michael Leavitt, who said in January 2005, “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs.

11.02.13 | By Kaelan Hollon
The old adage that 'you learn something new every day' doesn’t apply to the biopharmaceutical industry; for those researching and developing new medicine, it would be more accurate to say you learn something new every few minutes. Our member companies continue to push the limits of research, and that process keeps our work consistently exciting.  
11.01.13 | By Kristin Van Goor

Less than 15 years ago, submitting an application to the Food and Drug Administration (FDA) for the approval of a new medicine generally involved loading docks, moving trucks, and enough paper to obliterate a small tree farm.  Today, those data once supplied on hundreds of thousands of paper pages are now a structured collection of electronic files submitted to the FDA through a secure portal.